Literature DB >> 28669056

Pathogenic Th17 and Th22 cells are increased in patients with autoimmune thyroid disorders.

Marlen Vitales-Noyola1, Ana M Ramos-Levi2, Rebeca Martínez-Hernández2, Ana Serrano-Somavilla2, Miguel Sampedro-Nuñez2, Roberto González-Amaro1,3, Mónica Marazuela4.   

Abstract

PURPOSE: To study the levels of pathogenic and non-pathogenic Th17 and Th22 cells in autoimmune thyroid disorders patients. Although Th17 cells seem to play an important role in the pathogenesis of thyroid autoimmune disorders, the specific subsets of these lymphocytes have not been analyzed in this condition.
METHODS: We assessed the levels of Th17 (pathogenic and non-pathogenic) and Th22 cells in peripheral blood and thyroid glands of autoimmune thyroid disorders patients (n   =  26, 16 with Graves' disease and 10 with Hashimoto's thyroiditis) and 15 healthy controls by multi-parametric flow cytometry and immunofluorescence microscopy.
RESULTS: We found increased levels of pathogenic Th17 lymphocytes and Th22 cells in peripheral blood from autoimmune thyroid disorders patients. In addition, these cells were detected in thyroid glands from HT patients. Furthermore, we found significant correlations between the levels of these cells and disease activity, disease duration, and the presence of ophthalmopathy.
CONCLUSIONS: The increased levels of pathogenic Th17 lymphocytes and Th22 cells in autoimmune thyroid disorders suggest their involvement in the pathogenesis of this condition.

Entities:  

Keywords:  Autoimmune thyroiditis; Graves’ disease; Hashimoto’s thyroiditis; Th17 cells; Th22 cells

Mesh:

Substances:

Year:  2017        PMID: 28669056     DOI: 10.1007/s12020-017-1361-y

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  33 in total

1.  Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Authors:  Wolfgang Hueber; Bruce E Sands; Steve Lewitzky; Marc Vandemeulebroecke; Walter Reinisch; Peter D R Higgins; Jan Wehkamp; Brian G Feagan; Michael D Yao; Marek Karczewski; Jacek Karczewski; Nicole Pezous; Stephan Bek; Gerard Bruin; Bjoern Mellgard; Claudia Berger; Marco Londei; Arthur P Bertolino; Gervais Tougas; Simon P L Travis
Journal:  Gut       Date:  2012-05-17       Impact factor: 23.059

2.  Polyfunctional, Pathogenic CD161+ Th17 Lineage Cells Are Resistant to Regulatory T Cell-Mediated Suppression in the Context of Autoimmunity.

Authors:  Sharee A Basdeo; Barry Moran; Deborah Cluxton; Mary Canavan; Jennifer McCormick; Mary Connolly; Carl Orr; Kingston H G Mills; Douglas J Veale; Ursula Fearon; Jean M Fletcher
Journal:  J Immunol       Date:  2015-06-10       Impact factor: 5.422

Review 3.  T regulatory (Treg) and T helper 17 (Th17) lymphocytes in thyroid autoimmunity.

Authors:  Roberto González-Amaro; Mónica Marazuela
Journal:  Endocrine       Date:  2015-10-16       Impact factor: 3.633

4.  BREG cells in Hashimoto's thyroiditis isolated or associated to further organ-specific autoimmune diseases.

Authors:  Maria Giulia Santaguida; Ilenia Gatto; Giorgio Mangino; Camilla Virili; Ilaria Stramazzo; Poupak Fallahi; Alessandro Antonelli; Maria Segni; Giovanna Romeo; Marco Centanni
Journal:  Clin Immunol       Date:  2017-04-28       Impact factor: 3.969

Review 5.  Autoimmune thyroid disorders.

Authors:  Alessandro Antonelli; Silvia Martina Ferrari; Alda Corrado; Andrea Di Domenicantonio; Poupak Fallahi
Journal:  Autoimmun Rev       Date:  2014-10-25       Impact factor: 9.754

6.  Impairment of regulatory capacity of CD4+CD25+ regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves' disease.

Authors:  Chaoming Mao; Shu Wang; Yichuan Xiao; Jingwei Xu; Qian Jiang; Min Jin; Xiaohua Jiang; Hua Guo; Guang Ning; Yanyun Zhang
Journal:  J Immunol       Date:  2011-03-11       Impact factor: 5.422

7.  Serum levels of angiogenic molecules in autoimmune thyroid diseases and their correlation with laboratory and clinical features.

Authors:  Nicté Figueroa-Vega; Paloma Sanz-Cameno; Ricardo Moreno-Otero; Francisco Sánchez-Madrid; Roberto González-Amaro; Mónica Marazuela
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

8.  Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling.

Authors:  Stefanie Eyerich; Kilian Eyerich; Davide Pennino; Teresa Carbone; Francesca Nasorri; Sabatino Pallotta; Francesca Cianfarani; Teresa Odorisio; Claudia Traidl-Hoffmann; Heidrun Behrendt; Stephen R Durham; Carsten B Schmidt-Weber; Andrea Cavani
Journal:  J Clin Invest       Date:  2009-11-16       Impact factor: 14.808

9.  Functional interleukin-17 receptor A are present in the thyroid gland in intractable Graves disease.

Authors:  Jian-Rong Li; Fu-Yuan Hong; Jin-Yang Zeng; Guo-Liang Huang
Journal:  Cell Immunol       Date:  2013-02-19       Impact factor: 4.868

10.  Serum interleukin-23 (IL-23) is increased in Hashimoto's thyroiditis.

Authors:  Rosaria Maddalena Ruggeri; Salvatore Saitta; Mariateresa Cristani; Salvatore Giovinazzo; Valeria Tigano; Francesco Trimarchi; Salvatore Benvenga; Sebastiano Gangemi
Journal:  Endocr J       Date:  2014-01-28       Impact factor: 2.349

View more
  12 in total

1.  Increased levels of pathogenic Th17 cells and diminished function of CD69+ Treg lymphocytes in patients with overweight.

Authors:  Alejandra Mendoza-Pérez; Marlen Vitales-Noyola; Larisa González-Baranda; Crisol Álvarez-Quiroga; Berenice Hernández-Castro; Adriana Monsiváis-Urenda; Lourdes Baranda; Perla Niño-Moreno; Gilberto Hurtado; Raquel Sánchez-Gutiérrez; Roberto González-Amaro
Journal:  Clin Exp Immunol       Date:  2022-07-22       Impact factor: 5.732

2.  SLAM/SAP Decreased Follicular Regulatory T Cells in Patients with Graves' Disease.

Authors:  Lina Geng; Jun Yang; Xinyi Tang; Huiyong Peng; Jie Tian; Zhigang Hu; Yingzhao Liu; Huaxi Xu; Shengjun Wang
Journal:  J Immunol Res       Date:  2021-04-19       Impact factor: 4.818

Review 3.  Mechanisms That Underly T Cell Immunity in Graves' Orbitopathy.

Authors:  Sijie Fang; Yi Lu; Yazhuo Huang; Huifang Zhou; Xianqun Fan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-01       Impact factor: 5.555

4.  Identification of lncRNA and mRNA Expression Profile in Relapsed Graves' Disease.

Authors:  Qiuming Yao; Zhenyu Song; Bin Wang; Xi Jia; Ronghua Song; Jinan Zhang
Journal:  Front Cell Dev Biol       Date:  2021-12-01

Review 5.  The Role of Exposomes in the Pathophysiology of Autoimmune Diseases II: Pathogens.

Authors:  Aristo Vojdani; Elroy Vojdani; Avi Z Rosenberg; Yehuda Shoenfeld
Journal:  Pathophysiology       Date:  2022-06-03

6.  Changes in Th9 and Th17 lymphocytes and functional cytokines and their relationship with thyroid-stimulating hormone receptor antibodies at different stages of graves' disease.

Authors:  Xuan Ren; Hui Chen
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

Review 7.  Role of Th22 Cells in the Pathogenesis of Autoimmune Diseases.

Authors:  Qi Jiang; Guocan Yang; Fan Xiao; Jue Xie; Shengjun Wang; Liwei Lu; Dawei Cui
Journal:  Front Immunol       Date:  2021-07-06       Impact factor: 7.561

Review 8.  The exploration of Hashimoto's Thyroiditis related miscarriage for better treatment modalities.

Authors:  Yu Min; Xing Wang; Hang Chen; Guobing Yin
Journal:  Int J Med Sci       Date:  2020-08-29       Impact factor: 3.738

9.  Vasoactive intestinal peptide axis is dysfunctional in patients with Graves' disease.

Authors:  M Carrión; A M Ramos-Leví; I V Seoane; R Martínez-Hernández; A Serrano-Somavilla; D Castro; Y Juarranz; I González-Álvaro; Rosa P Gomariz; Mónica Marazuela
Journal:  Sci Rep       Date:  2020-08-03       Impact factor: 4.379

10.  Prevalence of autoimmune thyroid disease in patients with psoriasis: a meta-analysis.

Authors:  Xiaochao Zhang; Suhan Zhang; Ruifang Wu; Siying Li; Yuwen Su; Peng Zhang
Journal:  BMJ Open       Date:  2022-01-31       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.